Speeding Therapy Access Today Act of 2021
Latest action · Mar 10, 2021 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 10, 2021
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Speeding Therapy Access Today Act of 2021
This bill requires and authorizes various actions to accelerate the development of therapies for rare diseases.
The Food and Drug Administration (FDA) shall establish the Intercenter Institute on Rare Diseases and Conditions. The institute shall (1) coordinate engagement with relevant stakeholders, (2) build the FDA's expertise in the review of medical products to treat rare diseases, (3) coordinate regulatory science initiatives related to rare diseases, (4) establish and implement a program to make recommendations to address challenges associated with developing medical products to treat rare diseases in an individual or in very small populations, (5) convene a stakeholder meeting to consider potential amendments to labels for medical products to treat rare diseases, and (6) establish and carry out a program to facilitate voluntary communication between the sponsors of such medical products and third-party payers (e.g., insurance companies).
The bill also authorizes the FDA to make grants to assist in developing practices related to the development and production of individualized therapies or therapies to treat very small populations.
The bill also establishes an advisory committee to advise the FDA on issues related to the development of therapies to treat rare diseases.
Cosponsors 40
Members who signed on, in the order they did. Signatures ran from Mar 10, 2021 to Apr 21, 2022; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NC | G. K. Butterfield | Original | Mar 10, 2021 |
| D-FL | Darren Soto | Mar 16, 2021 | |
| D-FL | Alcee L. Hastings | Mar 23, 2021 | |
| D-NJ | Jefferson Van Drew | Apr 5, 2021 | |
| D-CA | Mike Levin | Apr 19, 2021 | |
| R-PA | John Joyce | Apr 26, 2021 | |
| R-NY | Claudia Tenney | May 11, 2021 | |
| R-IL | Rodney Davis | May 11, 2021 | |
| D-NV | Susie Lee | May 12, 2021 | |
| D-PA | Susan Wild | May 14, 2021 | |
| R-PA | Brian K. Fitzpatrick | May 17, 2021 | |
| D-NY | Antonio Delgado | May 18, 2021 | |
| R-AZ | Debbie Lesko | Jun 1, 2021 | |
| D-CA | Grace F. Napolitano | Jun 1, 2021 | |
| R-NY | Chris Jacobs | Jun 11, 2021 | |
| R-OK | Tom Cole | Jun 15, 2021 | |
| D-NC | Deborah K. Ross | Jul 22, 2021 | |
| D-DC | Eleanor Holmes Norton | Jul 22, 2021 | |
| R-PA | Mike Kelly | Jul 22, 2021 | |
| R-TN | David Kustoff | Aug 3, 2021 | |
| D-NJ | Josh Gottheimer | Aug 3, 2021 | |
| D-CA | Jared Huffman | Oct 15, 2021 | |
| D-CA | Mark DeSaulnier | Oct 15, 2021 | |
| D-MA | Stephen F. Lynch | Oct 21, 2021 | |
| D-MN | Dean Phillips | Dec 23, 2021 | |
| D-CO | Joe Neguse | Feb 8, 2022 | |
| R-PR | Jenniffer González-Colón | Feb 25, 2022 | |
| D-IA | Cynthia Axne | Mar 9, 2022 | |
| D-CA | Eric Swalwell | Mar 9, 2022 | |
| D-KY | John A. Yarmuth | Mar 9, 2022 | |
| D-PA | Madeleine Dean | Mar 9, 2022 | |
| D-GA | Sanford D. Bishop, Jr. | Mar 9, 2022 | |
| D-NM | Melanie A. Stansbury | Mar 11, 2022 | |
| D-AZ | Tom O'Halleran | Mar 11, 2022 | |
| D-CO | Jason Crow | Mar 15, 2022 | |
| R-SC | Joe Wilson | Mar 15, 2022 | |
| D-CA | Doris O. Matsui | Mar 18, 2022 | |
| R-AR | J. French Hill | Mar 18, 2022 | |
| R-OK | Markwayne Mullin | Mar 31, 2022 | |
| R-NE | Don Bacon | Apr 21, 2022 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Mar 10, 2021 |
| Health Subcommittee | Referred Mar 10, 2021 |
Actions 3
Everything that happened, newest first.
- Mar 10, 2021Introduced in House
- Mar 10, 2021Referred to the House Committee on Energy and Commerce.
- Mar 10, 2021Referred to the Subcommittee on Health.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 167, no. 45, March 10, 2021, page H1326.
Printed hearings 3
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 117-75 | THE FUTURE OF MEDICINE: LEGISLATION TO ENCOURAGE INNOVATION AND IMPROVE OVERSIGHT308 pages | Energy and Commerce Committee | Mar 17, 2022 |
| Serial No. 117-65 | HEARING ON; FDA USER FEE REAUTHORIZATION: ENSURING SAFE AND EFFECTIVE DRUGS AND BIOLOGICS229 pages | Energy and Commerce Committee | Feb 3, 2022 |
| Serial No. 117-30 | THE FISCAL YEAR 2022 HHS BUDGET143 pages | Energy and Commerce Committee | May 12, 2021 |
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 670 | Speeding Therapy Access Today Act of 2021 | Identical bill | Mar 10, 2021 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act to accelerate development of therapies across the spectrum of rare diseases and conditions and facilitate patient access to such therapies, and for other purposes.
- Short Title(s) as Introduced
- Speeding Therapy Access Today Act of 2021
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Advisory bodies
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Executive agency funding and structure
- Food and Drug Administration (FDA)
- Health
- Health technology, devices, supplies
- Manufacturing
- Medical research
- Research administration and funding
Text 1
Each version as it was printed, newest first.
- Mar 10, 2021Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
